CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-05-24): Decline in lung function, impaired response to salbutamol in HCV+ asthmatics

Clinical

Decline in lung function, impaired response to salbutamol in HCV+ asthmatics

Last Updated: 2004-05-24 12:45:17 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Chronic infection with hepatitis C virus (HCV) adversely affects lung function and airway responses to salbutamol in patients with asthma who fail to respond to interferon therapy, report two Japanese researchers in the June 1st issue of the American Journal of Medicine.

Drs. Hiroshi Kanazawa and Junichi Yoshikawa of Osaka City University prospectively followed 75 asthmatic patients for 6 years. Twenty were HCV-negative and 55 were HCV-positive. Of the HCV-positive group, 18 responded to a 6-month course of interferon (6 MIU three times/week) and 37 did not.

One year after interferon therapy, patients were treated in a double blind fashion with inhaled salbutamol (200 �g) or oxitropium bromide (200 �g).

During follow up, only interferon nonresponders showed a "significant decrease" in pre- and post-bronchodilator FEV1, the investigators report. Moreover, only these patients showed a steep decline in reversibility with salbutamol during follow up. In contrast, there was a steep increase in reversibility with oxitropium only in interferon nonresponders.

Significantly greater declines in the diffusing capacity of the lung for carbon monoxide were also noted during follow up in interferon nonresponders than in HCV-negative and interferon responders.

"It seems unlikely that interferon therapy directly influenced airway responses to salbutamol or oxitropium apart from its effect on HCV-induced airway responses," Drs. Kanazawa and Yoshikawa write.

"Therefore, our findings suggest that chronic HCV infection is associated with an accelerated decline in lung function and impaired responses to salbutamol in asthmatic patients," they conclude.

Am J Med 2004;116:749-752.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.